HOUSTON, Sept. 7,
2022 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors and
viruses, today announced that Walter
Klemp, President and Chief Executive Officer of Moleculin,
will present at the H.C. Wainwright 24th Annual Global
Investment Conference being held in New
York, NY and virtually on September
12-14, 2022.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference. For more information about the conference, please visit
the conference website.
A video webcast of the presentation will be available for
viewing on-demand through the H.C. Wainwright conference platform
beginning Monday, September 12 at
7:00 AM ET for 30-days to those
registered for the event.
About Moleculin Biotech,
Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of drug
candidates for the treatment of highly resistant tumors and
viruses. The Company's lead program, Annamycin, is a
next-generation anthracycline designed to avoid multidrug
resistance mechanisms with little to no cardiotoxicity. Annamycin
is currently in development for the treatment of relapsed or
refractory acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator designed to be capable of inhibiting
p-STAT3 and other oncogenic transcription factors while also
stimulating a natural immune response, targeting brain tumors,
pancreatic and other cancers; and WP1220, an analog to WP1066, for
the topical treatment of cutaneous T-cell lymphoma. Moleculin is
also engaged in the development of a portfolio of antimetabolites,
including WP1122, for the potential treatment of COVID-19 and other
viruses, as well as cancer indications including brain tumors,
pancreatic and other cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301619086.html
SOURCE Moleculin Biotech, Inc.